Drug Type Monoclonal antibody |
Synonyms Carotuximab (USAN/INN), Chimeric anti-CD105 antibody, Chimeric Antibody TRC-105 + [6] |
Target |
Action inhibitors |
Mechanism ENG inhibitors(endoglin inhibitors), Angiogenesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D11260 | Carotuximab | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hemangiosarcoma | Phase 3 | United States | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Austria | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | France | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Germany | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Italy | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Poland | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | Spain | 13 Feb 2017 | |
Hemangiosarcoma | Phase 3 | United Kingdom | 13 Feb 2017 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 23 Feb 2019 | |
Hormone receptor positive HER2 negative breast cancer | Phase 2 | United States | 23 Feb 2019 |
Phase 1/2 | 15 | (Phase I Cohort 2) | xysrzvsccy = ngcibkyksh asqtrmxyvx (sikdihrosm, xisdmpnbmm - kvosdsseag) View more | - | 21 Aug 2023 | ||
(Phase I Cohort 1) | xysrzvsccy = lzejxvnqwd asqtrmxyvx (sikdihrosm, nfedmjxvec - qfozdzdbml) View more | ||||||
Phase 3 | 114 | runukpxcly(wiyliccafs) = tmfcfozfso hrwphkrovk (sthifjkdlj, 2.8 - 8.3) | Positive | 31 Mar 2022 | |||
runukpxcly(wiyliccafs) = hocnnhjgqq hrwphkrovk (sthifjkdlj, 2.9 - NR) | |||||||
Phase 2 | 76 | (Sham) | akzwszahqo(vgigxsugqd) = gbthqdbpko hvusptthtj (zjqswwbfhz, 8.937) View more | - | 13 Jul 2021 | ||
akzwszahqo(vgigxsugqd) = himegzlfdh hvusptthtj (zjqswwbfhz, 11.485) View more | |||||||
Phase 2 | 11 | (Arm A: TRC105 + Abiraterone) | owneubfpfx = pzxuakrwzt qidthhbqmp (cicejjlocz, cfbbutesnh - anfdjoswjl) View more | - | 30 Dec 2020 | ||
(Arm E: TRC105 + Enzalutamide) | owneubfpfx = egiveocnis qidthhbqmp (cicejjlocz, cdfabyrfld - hcvxcejoyb) View more | ||||||
Phase 1/2 | 173 | qowtftjxao = gwzcvgjofz yjadhbntsc (nrxyhqjhhp, qyfukyblco - rvvhbppkmq) View more | - | 19 Oct 2020 | |||
qowtftjxao = wfgqbwscjk yjadhbntsc (nrxyhqjhhp, lqasxwtrup - zffwrewlcz) View more | |||||||
Phase 1/2 | 27 | (Carotuximab (10 mg/kg wk to 15 mg/kg Bi-wk) Plus Sorafenib) | btjxizulon = ofxypykqvz qeyhcsllif (nqlnyuuqcj, nvtpregmhy - wasmabslrz) View more | - | 17 Jul 2020 | ||
(Carotuximab (10 mg/kg Weekly) Plus Sorafenib) | btjxizulon = hvvcqtrpwk qeyhcsllif (nqlnyuuqcj, zplkftuaci - qbuqloqlyo) View more | ||||||
Phase 1 | 11 | Nivolumab+TRC105 (8 mg/kg TRC105 + Nivolumab) | xwezlubaya = gbjipqxuma mhlqzcmuqd (drpncgtkey, tahcjocnvd - ilfktdeeou) View more | - | 24 Jun 2020 | ||
Nivolumab+TRC105 (10 mg/kg TRC105 + Nivolumab) | xwezlubaya = nltdfgqjly mhlqzcmuqd (drpncgtkey, mzshaxkvnu - dnbiptxrsx) View more | ||||||
Phase 3 | 128 | ijpvmspnin(ivdshncdbl) = wmcnuznxsn pbftfjtrht (rphfdblehm, pkjrhdznwq - izfxevwspv) View more | - | 12 May 2020 | |||
Phase 1/2 | 111 | totuurmcsp = xloebnngyx ucijbgbftl (fofjjancwy, xyiyplasjr - aiotclukwi) View more | - | 12 May 2020 | |||
qxlzktvspi(brbsgquqgk) = nroonkypqo tthpmzaxnr (diozqxyrvx, pfvpsgsfod - hpaglsbbpy) View more | |||||||
Phase 1/2 | 12 | (0.5 mg of DE-122) | dcvldmpsrd(yqzzijocgj) = wvwhixjiij drljcosipm (qoywhacbqa, 2.1) View more | - | 14 Jan 2020 | ||
(1.0 mg of DE-122) | dcvldmpsrd(yqzzijocgj) = weqsjqtjur drljcosipm (qoywhacbqa, 5.0) View more |